1887

Journal of General Virology header logo

Volume 99, Issue 1

Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A Free

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease actively involved in regulating lipid homeostasis. Although PCSK9 has been shown to inhibit hepatitis C virus (HCV) entry and replication, the underlying mechanisms have not been thoroughly characterized. Moreover, whether PCSK9 regulates HCV translation and assembly/secretion has not been determined. We therefore further studied the effects of PCSK9 on the HCV life cycle. We showed that PCSK9 did not affect HCV translation or assembly/secretion. Overexpression of PCSK9 inhibited HCV replication in HCV genomic replicon cells in a dose-dependent manner and after cell culture-derived HCV (HCVcc) infection. Knocking down PCSK9 increased HCV replication. The gain-of-function (D374Y) or loss-of-function (Δaa. 31–52) PCSK9 mutants for low-density lipoprotein receptor (LDLR) degradation had no effect on HCV replication, suggesting that HCV replication inhibition by PCSK9 was not due to LDLR degradation. The uncleaved ProPCSK9, but not cleaved PCSK9, down-regulated HCV replication, suggesting that the auto-cleavage of PCSK9 affected HCV replication. We also found that PCSK9 interacted with NS5A through NS5A aa. 95–215, and this region played an important role in NS5A dimerization, NS5A-RNA binding and was essential for HCV replication. More importantly, NS5A dimerization and NS5A-RNA binding were suppressed by PCSK9 upon interaction. These results suggested that PCSK9 inhibited HCV replication through interaction with NS5A. Our study should help optimize anti-HCV treatment regimen in patients with abnormal lipid profiles.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): HCV replication , NS5A , NS5A dimerization , PCSK9 , protein interaction and RNA binding
© 2018 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000987
2018-01-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/99/1/44.html?itemId=/content/journal/jgv/10.1099/jgv.0.000987&mimeType=html&fmt=ahah

References

  1. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virol J 2011; 8:161 [View Article][PubMed]
     [Google Scholar]
  2. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59:318–327 [View Article][PubMed]
     [Google Scholar]
  3. Moradpour D, Penin F. Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol 2013; 369:113–142 [View Article][PubMed]
     [Google Scholar]
  4. Suzuki T, Aizaki H, Murakami K, Shoji I, Wakita T. Molecular biology of hepatitis C virus. J Gastroenterol 2007; 42:411–423 [View Article][PubMed]
     [Google Scholar]
  5. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61:S58–S68 [View Article][PubMed]
     [Google Scholar]
  6. Lauer GM. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J Infect Dis 2013; 207:S7–S12 [View Article][PubMed]
     [Google Scholar]
  7. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26:401–412 [View Article][PubMed]
     [Google Scholar]
  8. Li G, de Clercq E. Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res 2017; 142:83–122 [View Article][PubMed]
     [Google Scholar]
  9. D'Ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct-acting antivirals: the endgame for hepatitis C?. Curr Opin Virol 2017; 24:31–37 [View Article][PubMed]
     [Google Scholar]
  10. Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res 2014; 114:1022–1036 [View Article][PubMed]
     [Google Scholar]
  11. Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. Annu Rev Pharmacol Toxicol 2014; 54:273–293 [View Article][PubMed]
     [Google Scholar]
  12. Du F, Hui Y, Zhang M, Linton MF, Fazio S et al. Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J Biol Chem 2011; 286:43054–43061 [View Article][PubMed]
     [Google Scholar]
  13. Marais DA, Blom DJ, Petrides F, Gouëffic Y, Lambert G. Proprotein convertase subtilisin/kexin type 9 inhibition. Curr Opin Lipidol 2012; 23:511–517 [View Article][PubMed]
     [Google Scholar]
  14. Farnier M. PCSK9: from discovery to therapeutic applications. Arch Cardiovasc Dis 2014; 107:58–66 [View Article][PubMed]
     [Google Scholar]
  15. Poirier S, Mayer G. The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. Drug Des Devel Ther 2013; 7:1135–1148 [View Article][PubMed]
     [Google Scholar]
  16. Seidah NG, Sadr MS, Chrétien M, Mbikay M. The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. J Biol Chem 2013; 288:21473–21481 [View Article][PubMed]
     [Google Scholar]
  17. Lambert G, Charlton F, Rye KA, Piper DE. Molecular basis of PCSK9 function. Atherosclerosis 2009; 203:1–7 [View Article][PubMed]
     [Google Scholar]
  18. Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis 2011; 21:835–843 [View Article][PubMed]
     [Google Scholar]
  19. Labonté P, Begley S, Guévin C, Asselin MC, Nassoury N et al. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology 2009; 50:17–24 [View Article][PubMed]
     [Google Scholar]
  20. Syed GH, Tang H, Khan M, Hassanein T, Liu J et al. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J Virol 2014; 88:2519–2529 [View Article][PubMed]
     [Google Scholar]
  21. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 2007; 81:8374–8383 [View Article][PubMed]
     [Google Scholar]
  22. Hoffman B, Li Z, Liu Q. Downregulation of viral RNA translation by hepatitis C virus non-structural protein NS5A requires the poly(U/UC) sequence in the 3' UTR. J Gen Virol 2015; 96:2114–2121 [View Article][PubMed]
     [Google Scholar]
  23. Albecka A, Belouzard S, Op de Beeck A, Descamps V, Goueslain L et al. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 2012; 55:998–1007 [View Article][PubMed]
     [Google Scholar]
  24. Kosenko T, Golder M, Leblond G, Weng W, Lagace TA. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation. J Biol Chem 2013; 288:8279–8288 [View Article][PubMed]
     [Google Scholar]
  25. Dwyre DM, Fernando LP, Holland PV, Hepatitis B, Hepatitis C. and HIV transfusion-transmitted infections in the 21st century. Vox Sang 2011; 100:92–98 [Crossref]
     [Google Scholar]
  26. Poirier S, Hamouda HA, Villeneuve L, Demers A, Mayer G. Trafficking dynamics of PCSK9-induced LDLR degradation: focus on human PCSK9 mutations and C-terminal domain. PLoS One 2016; 11:e0157230 [View Article][PubMed]
     [Google Scholar]
  27. Schulz R, Schlüter KD, Laufs U. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol 2015; 110:4 [View Article][PubMed]
     [Google Scholar]
  28. Mayne J, Dewpura T, Raymond A, Bernier L, Cousins M et al. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin Chem 2011; 57:1415–1423 [View Article][PubMed]
     [Google Scholar]
  29. Ross-Thriepland D, Harris M. Hepatitis C virus NS5A: enigmatic but still promiscuous 10 years on!. J Gen Virol 2015; 96:727–738 [View Article][PubMed]
     [Google Scholar]
  30. Park C, Min S, Park EM, Lim YS, Kang S et al. Pim kinase interacts with nonstructural 5A protein and regulates hepatitis C virus entry. J Virol 2015; 89:10073–10086 [View Article][PubMed]
     [Google Scholar]
  31. Cordek DG, Bechtel JT, Maynard AT, Kazmierski WM, Cameron CE. Targeting the NS5A protein of HCV: an emerging option. Drugs Future 2011; 36:691–711 [View Article][PubMed]
     [Google Scholar]
  32. Gawlik K, Baugh J, Chatterji U, Lim PJ, Bobardt MD et al. HCV core residues critical for infectivity are also involved in core-NS5A complex formation. PLoS One 2014; 9:e88866 [View Article][PubMed]
     [Google Scholar]
  33. Lai CK, Saxena V, Tseng CH, Jeng KS, Kohara M et al. Nonstructural protein 5A is incorporated into hepatitis C virus low-density particle through interaction with core protein and microtubules during intracellular transport. PLoS One 2014; 9:e99022 [View Article][PubMed]
     [Google Scholar]
  34. Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CN. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol 2009; 83:4395–4403 [View Article][PubMed]
     [Google Scholar]
  35. Lambert SM, Langley DR, Garnett JA, Angell R, Hedgethorne K et al. The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. Protein Sci 2014; 23:723–734 [View Article][PubMed]
     [Google Scholar]
  36. Lim PJ, Chatterji U, Cordek D, Sharma SD, Garcia-Rivera JA et al. Correlation between NS5A dimerization and hepatitis C virus replication. J Biol Chem 2012; 287:30861–30873 [View Article][PubMed]
     [Google Scholar]
  37. Deng Q, Wang D, Xiang X, Gao X, Hardwidge PR et al. Application of a split luciferase complementation assay for the detection of viral protein-protein interactions. J Virol Methods 2011; 176:108–111 [View Article][PubMed]
     [Google Scholar]
  38. Nag A, Robotham JM, Tang H. Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors. J Virol 2012; 86:12616–12624 [View Article][PubMed]
     [Google Scholar]
  39. Melendez QM, Krishnaji ST, Wooten CJ, Lopez D. Hypercholesterolemia: the role of PCSK9. Arch Biochem Biophys 2017; 625-626:39–53 [View Article][PubMed]
     [Google Scholar]
  40. Shi Q, Hoffman B, Liu Q. PI3K-Akt signaling pathway upregulates hepatitis C virus RNA translation through the activation of SREBPs. Virology 2016; 490:99–108 [View Article][PubMed]
     [Google Scholar]
  41. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 2010; 21:33–40 [View Article][PubMed]
     [Google Scholar]
  42. Romero V, Fellows E, Jenne DE, Andrade F. Cleavage of La protein by granzyme H induces cytoplasmic translocation and interferes with La-mediated HCV-IRES translational activity. Cell Death Differ 2009; 16:340–348 [View Article][PubMed]
     [Google Scholar]
  43. Hwang J, Huang L, Cordek DG, Vaughan R, Reynolds SL et al. Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins. J Virol 2010; 84:12480–12491 [View Article][PubMed]
     [Google Scholar]
  44. Bridge SH, Sheridan DA, Felmlee DJ, Crossey MM, Fenwick FI et al. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. J Hepatol 2015; 62:763–770 [View Article][PubMed]
     [Google Scholar]
  45. Gopal K, Johnson TC, Gopal S, Walfish A, Bang CT et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44:335–340 [View Article][PubMed]
     [Google Scholar]
  46. Wu Q, Li Z, Mellor P, Zhou Y, Anderson DH et al. The role of PTEN - HCV core interaction in hepatitis C virus replication. Sci Rep 2017; 7:3695 [View Article][PubMed]
     [Google Scholar]
  47. Hazari S, Chandra PK, Poat B, Datta S, Garry RF et al. Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway. Virol J 2010; 7:36 [View Article][PubMed]
     [Google Scholar]
  48. Fan D, Yancey PG, Qiu S, Ding L, Weeber EJ et al. Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry 2008; 47:1631–1639 [View Article][PubMed]
     [Google Scholar]
  49. Hundt J, Li Z, Liu Q. The inhibitory effects of anacardic acid on hepatitis C virus life cycle. PLoS One 2015; 10:e0117514 [View Article][PubMed]
     [Google Scholar]
  50. Huang L, Sineva EV, Hargittai MR, Sharma SD, Suthar M et al. Purification and characterization of hepatitis C virus non-structural protein 5A expressed in Escherichia coli . Protein Expr Purif 2004; 37:144–153 [View Article][PubMed]
     [Google Scholar]
  51. Yi M. Hepatitis C virus: propagation, quantification, and storage. Curr Protoc Microbiol 2010 Chapter 15: Unit 15D 11 [View Article][PubMed]
     [Google Scholar]
  52. Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol 2007; 46:999–1008 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000987
Loading
Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A
J. Gen. Virol. 99, 44 (2018); https://doi.org/10.1099/jgv.0.000987
/content/journal/jgv/10.1099/jgv.0.000987
/content/journal/jgv/10.1099/jgv.0.000987
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error